EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSTNIG00000018343
Gene Symbol: PSMD4B
2 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSTNIG00000009705
Gene Symbol: PSMC1A
2 Cross references
281 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSTNIG00000005109
Gene Symbol: PSMC2
2 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSTNIG00000017682
Gene Symbol: PSMC3
2 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSTNIG00000005738
Gene Symbol: PSMC4
2 Cross references
1 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSTNIG00000018920
Gene Symbol: PSMC5
2 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSTNIG00000002009
Gene Symbol: PSMC6
2 Cross references
241 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSTNIG00000005248
Gene Symbol: PSMC6
2 Cross references
241 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSTNIG00000015566
Gene Symbol: PSMD1
2 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSTNIG00000011164
Gene Symbol: PSMD11
2 Cross references
207 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSTNIG00000005173
Gene Symbol: PSMD12
2 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSTNIG00000005024
Gene Symbol: PSMD13
2 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).